Thats why we combed Reddit to find out what people are currently talking about in obesity and GLP-1 communities and asked the following medical experts to respond to readers most pressing questions: Kia Mitchell, MD Double board-certified family and obesity medicine physician and founder of the International Womens Obesity Network Marsha Novick, MD, FAAFP Spokesperson for The Obesity Society and board member of the American Board of Obesity Medicine Richele Corrado, DO, MPH Spokesperson for The Obesity Society and medical director, internist, and obesity medicine physician at Revolution Medicine, Health & Fitness Sherrie Singh-Bryan, PharmD, CDCES Clinical pharmacist and certified diabetic care and education specialist at Winn Army Community Hospital in Fort Stewart, Georgia Editors note: These interviews have been edited for length and clarity
Journal of Clinical Gastroenterology, 47 (5), 375-376
Disclosures: Andrea Lindfors: Gilead Sciences: The study was partly financed by Gilead Sciences, Hannes Hagstrm: Nothing to Disclose, Rickard Strandberg: Nothing to Disclose 853 AGILE3+ ENCOMPASSES THE TWO-STEP APPROACH NEEDED TO ENHANCE DIAGNOSTIC ACCURACY OF ADVANCED FIBROSIS IN PATIENTS WITH SUSPECTED MASLD Savvoula Savvidou 1 Polyxeni Agorastou 2 Effrosyni Tsirogianni 2 Stefania Kiapidou 2 Ioanna Papagiouvani 2 Theodora Oikonomou 2 Lazaros Sideras 2 Prodromos Hytiroglou 3 Ioannis Goulis 2 , 1 Hippokrateio University Hospital of Thessaloniki, 2 Hippokrateio University Hospital of Thessaloniki, Greece, 3 Department of Pathology, Medical School of Aristotle University of Thessaloniki Background: According to national Greek guidelines (2021) regarding diagnostic approach of suspected Metabolic dysfunction Associated Steatotic Liver Disease (MASLD), liver stiffness measurement (LSM) is suggested only to patients (pts) with ultrasonographic evidence of fatty liver, presence of at least one cardiometabolic factor in the absence of other aetiology for secondary hepatic steatosis (alcohol, drugs, viral hepatitis, etc), and intermediate risk for advanced fibrosis assessed by FIB-4 score
Even if it does, inexplicably, it doesnt include Zepbound, which is now the U.S
Patients experiencing urinary changes during GLP-1 therapy can implement several practical strategies to manage symptoms whilst continuing beneficial treatment
GLP-1 medications have rapidly accelerated this challenge, becoming one of the fastest-growing and most expensive line items in employer health plans
